Tissue Engineering Bone Using Autologous Progenitor Cells in the Peritoneum

Jinhui Shen1, Ashwin Nair1, Ramesh Saxena2, Cheng Cheng Zhang3, Joseph Borrelli Jr.4, Liping Tang1,5

1 Department of Bioengineering, University of Texas at Arlington, Arlington, Texas, United States of America, 2 Division of Nephrology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America, 3 Departments of Physiology and Developmental Biology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America, 4 Texas Health Physicians Group, Texas Health Arlington Memorial Hospital, Arlington, Texas, United States of America, 5 Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan

Abstract

Despite intensive research efforts, there remains a need for novel methods to improve the ossification of scaffolds for bone tissue engineering. Based on a common phenomenon and known pathological conditions of peritoneal membrane ossification following peritoneal dialysis, we have explored the possibility of regenerating ossified tissue in the peritoneum. Interestingly, in addition to inflammatory cells, we discovered a large number of multipotent mesenchymal stem cells (MSCs) in the peritoneal lavage fluid from mice with peritoneal catheter implants. The osteogenic potential of these peritoneal progenitor cells was demonstrated by their ability to easily infiltrate decalcified bone implants, produce osteocalcin and form mineralized bone in 8 weeks. Additionally, when poly(l-lactic acid) scaffolds loaded with bone morphogenetic protein-2 (a known osteogenic differentiation agent) were implanted into the peritoneum, signs of osteogenesis were seen within 8 weeks of implantation. The results of this investigation support the concept that scaffolds containing BMP-2 can stimulate the formation of bone in the peritoneum via directed autologous stem and progenitor cell responses.

Introduction

Bone loss often occurs as a result of open fractures, osteomyelitis, fractures which fail to heal, congenital malformations, tumors, and in a more general sense, osteoporosis. In recent years, significant progress has been made in the development of tissue engineered bone designed to replace or bridge large bone defects [1–3]. Typical tissue engineering strategies involve the use of an implant, usually in the form of a 3-dimensional scaffold, which integrates with existing bone tissue to restore bone and to some extent, the function of the damaged bone [4–6]. In recent years, adult mesenchymal stem cells (MSCs) have shown great promise in regenerating tissue engineered tissues and organs [7,8]. However, these approaches are still plagued by limitations associated with the recovery, differentiation ability and survival of autologous MSCs [9–13]. Therefore, there remains a need for better means to generate functional tissue by tissue engineering techniques, including bone.

Ossification of the peritoneum is a pathological condition often associated with patients undergoing peritoneal dialysis (PD) or as a result of traumatic splenic rupture or peritonitis [14–16]. Although inflammatory responses are believed to contribute to peritoneal ossification [15], the process(es) governing peritonitis-mediated ossification is not clear. Recent studies carried out in our laboratories have found that biomaterial-mediated inflammatory responses can prompt the recruitment of MSCs with multipotency, including osteogenic potential/activities [17]. In addition, we have recently discovered that the implantation of peritoneal catheters prompts the immigration of MSCs to the peritoneal cavities in humans (unpublished results). Based on these observations, we assume that, with the localized release of an osteogenic agent, the recruited MSCs would differentiate into osteoblasts to promote mineralization of tissue engineered bone scaffolds in situ.

To test this hypothesis, we first analyzed the compositions and osteogenic properties of progenitor cells in lavage fluids of animals following intraperitoneal implantation of biomaterials. Using decalcified bone matrix as an osteoconductive material, we developed and used poly l-lactic acid (PLLA) scaffolds, combined with bone morphogenetic protein-2 (BMP-2), and evaluated the potential for stimulating the production of viable bone in the peritoneum by inducing osteogenic reactions from autologous progenitor cells.

Materials and Methods

Ethics Statement

The animal use protocols (A11-008, A07-030) were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Texas at Arlington.
Materials

Goat anti-mouse SCF and Nanog antibodies and rabbit anti-mouse antibodies were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-mouse CD45, Sca-1, c-kit, CD34, FLK2, CD3, B220, TER-119, antibodies (rat anti mouse) to various stem cell markers CD105, CD29 and CD44, along with secondary antibody streptavidin PE/Cy5.5, and donkey anti-rat – APC were obtained from eBioscience (San Diego, CA, USA). Rat anti mouse CD105 was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Biotin conjugated lineage antibody cocktail was obtained from Miltenyi Biotec (Miltenyi Biotec Inc, Auburn, CA). Bone morphogenetic protein-2 (BMP-2) was obtained from R&D Systems (R&D Systems, Minneapolis, MN). PLLA was obtained from Medisorb 100L 1A (Lakeshore Biomaterials, AL, USA) with inherent viscosity of 1.9 dL/g.

Methods

Mouse peritoneal cell collections. Balb/c mice (4–6 months) were used in this experiment. Mice were implanted with polyurethane umbilical vessel catheter (2 cm length, 5.0 FR, Sentry Medical Products, Lombard, IL, USA) based on modified procedure published earlier [18,19]. Briefly, the mice were sedated with Isoflurane inhalation. Following sterilization with 70% ethanol, a small incision (~5 mm) was made and two sections of catheter were implanted in the peritoneal cavities. The incisions were then closed with stainless steel wound clips. After implantation, the mice were euthanized at different times (0 h, 6 h, 12 h, 18 h, 1 d, 2 d, 4 d, 7 d, 10 d, 14 d) with carbon dioxide inhalation. The peritoneal cells were then recovered via peritoneal lavage fluid. After 18 h, 1 d, 2 d, 4 d, 7 d, 10 d, 14 d) with carbon dioxide inhalation. The peritoneal cells were then recovered via peritoneal lavage fluid.

Flow cytometry analyses and cell differentiation of peritoneal progenitor cells. For flow cytometry analysis, RBC lysing buffer (Sigma Chemical Co., St Louis, MO) was used to remove red blood cells from each sample following the manufacturer’s instructions as previously described [20]. The cell density was adjusted to 5×10⁶/ml and then stained with monoclonal antibodies including anti-mouse CD105, CD29, CD45, CD44, CD3, B220, Mac-1, TER-119, or biotin conjugated lineage antibody cocktail (CD3, B220, TER-119, antibodies (rat anti mouse) to CD45, Sca-1, c-kit, CD34, Kit, B220, TER-119, Melinenyi Biotec), Streptavidin secondary antibody, Sca-1, c-kit, CD34, FLK2. Lin- Sca-1+Kit+CD34+FLK2- are widely used markers for long term hematopoietic stem cells (HSCs) [20,21], while CD105+CD29+CD44+CD45- is well recognized as the marker set for MSCs [22,23]. Stained cells were analyzed on BD FACSCalibur (BD Bioscience, San Jose, USA) to determine the types and percentages of peritoneal cells. Osteogenic differentiation of peritoneal progenitor cells was performed on confluent cells in the presence of recombinant BMP-2 (R&D Systems, Minneapolis, MN) for 3 weeks as previously described [24]. Calcium-rich deposits by osteoblasts were then evaluated using Alizarin Red S staining [24]. Adipogenic, neurogenic and myogenic differentiation of peritoneal progenitor cells was performed and analyzed similar to earlier publications [17].

Induced bone formation in peritoneum. Both decalcified bone collagen scaffolds and porous PLLA scaffolds were used for triggering bone formation in the peritoneum. It is well established that decalcified bone scaffolds contain necessary bone morphogenetic protein for inducing bone formation [25,26]. Decalcified femur bone scaffolds (~1.5 mm×1 mm×15 mm in size) were prepared according to published procedures [27,28]. It is estimated that there are 3 mg of BMP-2 per gram of demineralized dentin [29], and ~50–100 ng of a combination of BMPs per 25 mg of bovine bone matrix [30]. PLLA scaffolds were fabricated following salt leaching technique [31]. PLLA scaffolds have been widely used in bone tissue engineering research [32,33]. For this study, PLLA scaffolds were fabricated based on optimal scaffold design criteria related to pore size and structure, as established previously [34–37]. To stimulate localized osteogenic differentiation, ethanol sterilized PLLA scaffolds (5 mm×5 mm×5 mm in size with a pore size of 150 to 300 μm) were immersed in osteogenic differentiation solution (complete medium supplemented with 50 μg/ml ascorbic acid-2-phosphate, 10 mM dexamethasone, 7 mM β-glycerophosphate, and 1 μg/ml BMP-2) overnight, then lyophilized prior to implantation. BMP-2 is a known osteogenic differentiation agent and a few studies have shown high levels of osteogenic activities in various stem cells at 10–50 ng/ml [38,39]. Our pilot studies have shown that the in vivo release rates are approximately 5% (~50 ng) per scaffold per day for a period of 2 weeks. For in vivo testing, the scaffolds, including untreated scaffolds as control, were implanted in the peritoneal cavities [18,19]. The implants were isolated at 16 hours, 2, 6 and 12 weeks for histological evaluation.

Histological Evaluation of peritoneal implants. All ex- plants were frozen, cryosectioned, fixed, and used for various histological evaluations as described earlier [17,40]. H&E stain was used for providing a general overview of tissue structures. Immunohistochemical analyses were performed for assessing the presence of stem and progenitor cell markers including: SCF and Nanog, and osteoblast markers - osteocalcin and alkaline phosphatase - based on previous studies [40]. Alkaline phosphatase activity (AP activity) was tested using a biochemical assay obtained from Sigma (St. Louis, MO, USA). Calcium content change was tested by Alizarin Red S staining and von Kossa staining. All stained sections were observed under light microscopy (Leica DM LB) and the images analyzed using ImageJ, as described earlier [17,40].

Statistical analyses. The extent of cell recruitment, stem cell marker expression and mineralization were analyzed using One way ANOVA. PLLA scaffold mineralization at the end of 8 weeks was evaluated using Student’s-t-test. The statistical significance was determined at p<0.05.

Results

Recruitment and characterization of peritoneal fluid cells following dialysis in mice

A murine peritoneal implantation model was used to study the feasibility of using the peritoneum as a site for in vivo tissue regeneration. For that, it was essential to first investigate the cell populations that exist/arrive in the mice peritoneum following introduction of an implant. Polyurethane umbilical vessel catheters (2 cm in length) were implanted into the mouse (n = 5) peritoneal cavity to mimic the trauma and foreign body response caused by peritoneal dialysis procedures. After catheter implantation, peritoneal lavege fluid was collected at various time points up to day 14 from both catheter-implanted and control animals. Not surprisingly, after implantation for 2 days, we predominantly observed a number of inflammatory cells like T-cells (5.3±0.52%), B-cells (17.2±0.94%), myeloid cells (64.8±0.58%) and erythroid cells (4±0.41%) (Figure 1A). Interestingly, we also found that there were two unique sub-populations in the effluent cells that shared markers identical to those of MSCs (CD105+CD44+CD29+CD45-) and HSCs (Lin- Sca-1+Kit+CD34+FLK2-) in nearly each of the animals, these cells accounted for 0.29±0.04% and 0.03±0.01% respectively (Figure 1A–B). Interestingly, peritoneal MSCs also express many
progenitor cell markers, including CD8a, CD29, CD44, CD54, CD73, CD105, CD106, Stem Cell Factor (SCF), SH-3, Nanog, SSEA-3, and vimentin (Figure 1C). They also stained negative for CD10, CD11b, CD11c, CD13, CD14, CD19, CD30, CD34, CD45, CD49e, CD90, CD95, CD117, CD166, Nestin, Neurofilament-N, STR-1, TRA-1-81, or alpha-smooth muscle actin. Similar cells were also identified from the peritoneal effluents of human patients with End Stage Renal Disease (ESRD) (unpublished observation). To test the functionality and plasticity of these peritoneal progenitor cells, we assessed their multipotency by culturing them in vitro in the presence of various differentiation-inducing media. Specifically, the undifferentiated cells exhibited fibroblast-like morphology; the culture of these cells in specific differentiation mediums led to differentiation into osteogenic, adipogenic, neurogenic and myogenic phenotypes (Figure 1D). Collectively, these results suggest that the implantation of catheters in the peritoneum of adult mice prompted the migration of multipotent MSCs and other progenitor cells that express markers similar to those expressed on bone marrow stem cells into the area.

Calcification of decalcified bone implants

To determine the ability of these MSCs cells to form bone tissue in the peritoneum, we initially used decalcified bone scaffolds (approximately 1.5 mm×1 mm×15 mm in size). By doing so, we were able to study the ability of intraperitoneally implant-recruited MSCs to differentiate into bone forming cells and to produce mineralized bone tissue. Since peritoneal MSCs were found to express SCF and Nanog, both markers were used to assess the extent of MSC recruitment following scaffold implantation. H&E staining of the bone scaffolds showed an increase in eosin staining from 16 hours to 12 weeks along with high cell infiltration by 12 weeks (Figure 2A). Interestingly, shortly after implantation (16 hour), there were many recruited cells including SCF+ and Nanog+ progenitor cells and an increased number on the surfaces of scaffold implants (Figure 2A). As expected, implant-associated osteoblast activity remained low as reflected by slight osteocalcin production on the tissue: scaffold interface of all the evaluated time points. After two weeks, SCF+/Nanog+ progenitor cells (stained in green) were found to be almost 2 times that found at 16 hours, indicating the recruitment and infiltration of progenitor cells into bone scaffolds (Figure 2B). The numbers of SCF+/Nanog+ cells remained the same through week 6 and were substantially reduced in number by week 12. By week 2, osteocalcin expression increased almost 2 times compared to that at the end of 16 hours. By 6 weeks this increase was almost 3 times, and by week 12 osteocalcin expression was almost 4 times that at 16 hours. Interestingly, over the 6 to 12 week period as the levels of osteocalcin increased, the expression of SCF and Nanog returned to the same levels as that at the end of 16 hours, suggesting the differentiation of the SCF+/Nanog+ progenitor cells into osteocalcin+ osteoblasts.

Figure 1. Multipotent MSCs exist in Balb/c mice peritoneal effluents. (A) Peritoneal cell population from animals with 2 day implants. (B) Recruitment of inflammatory cells and MSCs in mice peritoneal cavity after catheter implantation. (C) Expression of surface markers on peritoneal MSCs. (D) Peritoneal cells differentiated into specific lineages appropriate conditions. Morphology of undifferentiated cells is compared with cells differentiating into specific lineages like osteogenic (Alizarin Red S stain), adipogenic (Oil Red O stain), myogenic (α-smooth muscle actin) and neurogenic (NF-M and Class III β-tubulin stain). (Mag 200×, scale bar 100 μm, statistical significance of cell numbers at various time points tested using One Way ANOVA, *p<0.05). doi:10.1371/journal.pone.0093514.g001
Mineralization in decalcified bone implants

Mineralization of the decalcified bone scaffolds in the peritoneum was determined based on alkaline phosphatase (AP) activity, Alizarin Red S staining and von Kossa staining (Figure 3A). The area fraction of the implants that were mineralized was determined using ImageJ (Figure 3B). We found that AP activity increased at week 2 and that the tissue associated AP activity remained stable from weeks 2 to 12. Alizarin Red S stain (orange or red) and von Kossa stain (brown or black deposits) were also carried out to assess scaffold mineralization. There was no significant increase in calcium content between 16 hours to 2 weeks. However, scaffold mineralization dramatically increased during the period between week 6 and 12 by more than 7 fold compared to the 16 hours to 2 weeks period.

Ossification of scaffolds implanted within the peritoneum

Use of decalcified bone scaffolds to induce osteogenic differentiation of stem and progenitor cells in the peritoneum is not a clinically relevant approach. To find an alternative bone tissue engineering strategy, subsequent studies were carried out using poly-lactic acid (PLLA) polymer scaffolds that were loaded with BMP-2, which is an osteogenic differentiation agent and has been used clinically for bone tissue engineering [41,42]. Interestingly, even without stem cell pre-seeding, PLLA scaffolds promote the recruitment of MSCs (~0.35±0.10%) by day 3. By week 8, we found substantial infiltration of cells into the scaffolds (as seen by the H&E staining). Coincidently, many infiltrated cells expressed osteocalcin, indicating osteoblast activity (Figure 4A). There was a nearly 5 fold increase in osteocalcin expression (Figure 4B). Signs of mineralization in the form of calcium and phosphate deposits were observed within the scaffold as well (Figure 4C). Quantification of these markers of osteogenic activity showed a 5 fold increase in mineralization at the end of 8 weeks in PLLA scaffolds loaded with osteogenic differentiation agent BMP-2 (Figure 4D).

Discussion

For years, peritoneum has been used for evaluating host responses to biomaterials that have subsequently been employed in human subjects to meet clinical needs [18,43–49]. Recently, a few studies have even explored the possibility of using the peritoneum to grow visceral organs like bladder, uterus and vas deferens [50,51]. Most of these organ/tissue regeneration strategies involve the transplantation of cell-seeded scaffolds. Additional studies attempted to grow blood vessels by implanting biomaterials into...
peritoneum [52,53]. These studies showed that free-floating implants within the peritoneum acquired layers of macrophage derived myofibroblasts and collagen matrix along with mesothelial cells and undifferentiated cells bearing markers similar to those expressed on bone marrow stem cells [52,53]. Although several recent works, including ours, indicated the presence of progenitor cells in the peritoneum [53–55], the potential of using peritoneal stem cells for tissue engineering application has not been explored. Since tissue calcification has been observed following peritoneal dialysis, and splenic rupture [18,44,46–48,56], it is possible that pathogenic processes might lead to recruitment and osteogenic differentiation of progenitor cells in the peritoneum. To support these observations, we found that progenitor cells expressing various MSC surface markers were recruited to peritoneal implants with their numbers increasing dramatically until day 4, post implantation. Based on the expression of cell surface markers and lineage specific differentiation, we found that the peritoneal stem cells were similar to bone marrow stem cells [17,57]. Such cells were multipotent, as they had the ability to differentiate into osteogenic, adipogenic, neurogenic and myogenic phenotypes.

The formation of mineralized bone tissue in the peritoneum is a unique phenomenon that may be related to a disease - peritoneal ossification (PO). The cause of PO is not fully understood. However, it is generally believed that chronic inflammatory responses associated with peritoneal dialysis may be responsible [68–70]. It is possible that mineralized scaffolds and PO share a similar mechanism [16]. In fact, a few studies have suggested that an inflammatory stimulus, as that associated with implantation in the peritoneum, could lead to osteogenic cell migration from surrounding bone into the peritoneum or the inflammatory stimulus acts on stem cells to produce mesoblasts and osteoblasts [69,71,72].

While this phenomenon opens up a new vista in tissue regenerative strategies, there are additional opportunities for osteogenic differentiation is essential for stem cell-mediated bone regeneration [64]. To promote osteogenic differentiation of peritoneal stem cells, we first used decalcified bone scaffolds and then BMP-2-loaded PLLA scaffolds. It is well established that decalcified bone scaffolds contain osteogenic agents essential for osteogenic differentiation [65,66]. We found the presence of SCF+/Nanog+ progenitor cells reached their peak within 2 weeks of implantation and the cell density remained stable for up to 6 weeks, post implant. However, after week 6, the reduction of SCF+/Nanog+ progenitor cell number coincided with an increase of osteoblast osteocalcin activities and bone mineralization. A recent study has reported elevated expression of Nanog during undifferentiated state of stem cells followed by a drop in the levels upon osteoblastic differentiation [67]. Our results support that scaffold-containing osteogenic agents prompted the differentiation of progenitor cells into osteoblasts.

Osteogenic differentiation is essential for stem cell-mediated bone regeneration [64]. To promote osteogenic differentiation of peritoneal stem cells, we first used decalcified bone scaffolds and then BMP-2-loaded PLLA scaffolds. It is well established that decalcified bone scaffolds contain osteogenic agents essential for osteogenic differentiation [65,66]. We found the presence of SCF+/Nanog+ progenitor cells reached their peak within 2 weeks of implantation and the cell density remained stable for up to 6 weeks, post implant. However, after week 6, the reduction of SCF+/Nanog+ progenitor cell number coincided with an increase of osteoblast osteocalcin activities and bone mineralization. A recent study has reported elevated expression of Nanog during undifferentiated state of stem cells followed by a drop in the levels upon osteoblastic differentiation [67]. Our results support that scaffold-containing osteogenic agents prompted the differentiation of progenitor cells into osteoblasts.

The formation of mineralized bone tissue in the peritoneum is a unique phenomenon that may be related to a disease - peritoneal ossification (PO). The cause of PO is not fully understood. However, it is generally believed that chronic inflammatory responses associated with peritoneal dialysis may be responsible [68–70]. It is possible that mineralized scaffolds and PO share a similar mechanism [16]. In fact, a few studies have suggested that an inflammatory stimulus, as that associated with implantation in the peritoneum, could lead to osteogenic cell migration from surrounding bone into the peritoneum or the inflammatory stimulus acts on stem cells to produce mesoblasts and osteoblasts [69,71,72].

While this phenomenon opens up a new vista in tissue regenerative strategies, there are additional opportunities for
further advancement. For example, better designed scaffolds which can release bioactive chemokines at a more desirable rate could possibly enhance this bone formation phenomenon. We have made further advancement in scaffold development and investigated bone regeneration in critical sized defect models [26]. This study indicates the suitability of the peritoneal environment for autologous progenitor cell recruitment and differentiation into bone. These findings can pave the way for future research by exploring smarter materials to facilitate the development of more efficient strategies that engineer bone in vivo in the peritoneum so it can be readily transplanted to the defective sites, such as critical size defects, as needed.

**Author Contributions**

Conceived and designed the experiments: LT JS. Performed the experiments: JS. Analyzed the data: JS AN. Contributed reagents/materials/analysis tools: RS CCZ JB LT. Wrote the paper: JS AN.

**References**

1. Holzworth JM, Ma PX (2011) Biomimetic nanofibrous scaffolds for bone tissue engineering. Biomaterials 32: 9622–9629.
2. Patel ZS, Younis S, Tahhan Y, Jansen JA, Wong ME, et al. (2008) Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone 43: 931–940.
3. Huang YC, Kaigler D, Rice KG, Keeshbach PH, Mooney DJ (2005) Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. J Bone Miner Res 20: 848–857.
4. Diao H, Wang J, Shen C, Xia S, Guo T, et al. (2009) Improved cartilage regeneration utilizing mesenchymal stem cells in TGF-beta1 gene-activated scaffolds. Tissue Eng Part A 15: 2687–2696.
5. Shin M, Yoshimoto H, Vacanti JP (2004) In vivo bone tissue engineering using mesenchymal stem cells on a novel electrospun nanofibrous scaffold. Tissue Eng 10: 33–41.
6. Wayne JS, McDowell CL, Shields KJ, Tsou RN (2005) In vivo response of polyactic acid-alginate scaffolds and bone marrow-derived cells for cartilage tissue engineering. Tissue Eng 11: 953–963.
7. Caplan AI (2007) Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213: 341–347.
8. Meinel L, Karageorgiou V, Fajardo R, Snyder B, Shinde-Patil V, et al. (2004) Bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. Ann Biomed Eng 32: 112–122.
9. Stocum DL, Zapun GK (2006) Stretching the limits: stem cells in regeneration science. Dev Dynamics 237: 3648–3671.
10. Ikkada Y (2006) Challenges in tissue engineering. J R Soc Interface 3: 589–601.
11. Laschke MW, Harder Y, Amon M, Martin I, Farhadi J, et al. (2006) Angiogenesis in tissue engineering: breathing life into constructed tissue. J Cell Mol Med 10: 2293–2310.
12. Bonah MM, Alikomaheddal K, Talebian F, Ghaffari SH, Ghamvazadeh A, et al. (2006) Aging of mesenchymal stem cell in vitro. BMC Cell Biol 7: 14.
13. Criostomo PR, Wang M, Wairink GM, Morrell ED, Terrell AM, et al. (2006) High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock 26: 575–580.
14. Ioanidi O, Sekoulis A, Paraskakis G, Kotonis A, Chatzopoulos S, et al. (2012) Intra-abdominal heterotopic ossification of the peritoneum following traumatic injury. J Trauma 72: 92–95.
15. Agarwal A, Yeh BM, Breiman RS, Quayyum A, Coakley FV, et al. (2004) Peritoneal bone tissue engineering using human mesenchymal stem cells and porous silk scaffolds. Biomaterials 25: 129–138.
16. Shin M, Yoshimoto H, Vacanti JP (2004) In vivo bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. Ann Biomed Eng 32: 112–122.
17. Agarwal A, Yeh BM, Breiman RS, Quayyum A, Coakley FV, et al. (2004) Peritoneal bone tissue engineering using human mesenchymal stem cells and porous silk scaffolds. Biomaterials 25: 129–138.
18. Ho MH, Kuo PY, Hsieh HJ, Hsien TY, Hou LT, et al. (2004) Preparation of porous J Cell Physiol 213: 341–347.
19. Hu WJ, Eaton JW, Ugarova TP, Tang L (2001) Molecular basis of biomaterial-growth factor-beta1 on osteoblast differentiation. Bone 29: 323–330.
20. Takahashi S, Iwata H, Hanamura H (1987) Nature of bone morphogenetic protein-DMP from decalcified rabbit bone matrix. Nihon Seikigaku Gakkai Zasshi 61: 197–204.
21. Urist MR, Strates BS (1971) Bone morphogenetic protein. J Dent Res 50: 1392–1400.
22. Chartoff EH, Damez-Werno D, Sonntag KC, Hassinger L, Kaufmann DE, et al. (2004) Ossification mediated foreign body reactions. Blood 98: 1231–1238.
23. Soleimani M, Nadri S (2009) A protocol for isolation and culture of human mesenchymal stem cells. J Tissue Eng Regen Med 2: 1–13.
24. Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, et al. (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106–2111.
25. Mizutani H, Mera K, Ueda M, Iwata H (1996) A study of the bone morphogenetic protein derived from bovine denimized dental matrix. Nagoya Journal of Medical Sciences 59: 37–47.
26. Sampaio TK, Malakal JC, Hauschka PV, Jones WK, Sasah H, et al. (1992) Reconstituting human osteogenic protein-1 (OCP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 267: 20352–20362.
27. King RD, Brown B, Hwang M, Jeon T, George AT (2010) Fractal dimension analysis of the cortical ribbon in mild Alzheimer’s disease. Neuroimage 53: 471–477.
28. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, et al. (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106–2111.
29. Mizutani H, Mera K, Ueda M, Iwata H (1996) A study of the bone morphogenetic protein derived from bovine denimized dental matrix. Nagoya Journal of Medical Sciences 59: 37–47.
49. Najman S, Savic V, Djordjevic L, Ignjatovic N, Uskokovic D (2004) Biological evaluation of hydroxyapatite/poly-L-lactide (HAp/PLLA) composite biomaterials with poly-L-lactide of different molecular weights intraperitoneally implanted into mice. Bio-Medical Materials and Engineering 14: 61–70.

50. Campbell GR, Turnbull G, Xiang L, Haines M, Armstrong S, et al. (2008) The peritoneal cavity as a bioreactor for tissue engineering visceral organs: bladder, uterus and vas deferens. J Tissue Eng Regen Med 2: 50–60.

51. Cao Y, Zhang B, Croll T, Rolfe BE, Campbell JH, et al. (2008) Engineering tissue tubes using novel multilayered scaffolds in the rat peritoneal cavity. J Biomed Mater Res A 87: 719–727.

52. Campbell JH, Efendy JL, Han CL, Campbell GR (2000) Blood vessels from bone marrow. Ann N Y Acad Sci 902: 224–229.

53. Chue WL, Campbell GR, Caplice N, Muhammed A, Berry CL, et al. (2004) Engineering tissue tubes using novel multilayered scaffolds in the rat peritoneal cavity. J Biomed Mater Res A 87: 719–727.

54. Vranken I, De Visscher G, Lebacq A, Verbeken E, Flameng W (2008) The recruitment of primitive Lin(–) Sca-1(+), CD34(+), c-kit(+) and CD271(+) cells during the early intraperitoneal foreign body reaction. Biomaterials 29: 797–808.

55. Le SJ, Gongora M, Zhang B, Grimmond S, Campbell GR, et al. (2010) Gene expression profile of the fibrotic response in the peritoneal cavity. Differentiation 79: 232–243.

56. Matthews BD, Mostafa G, Carbonell AM, Jools CS, Kercher KW, et al. (2005) Evaluation of adhesion formation and host tissue response to intra-abdominal polytetrafluoroethylene mesh and composite prosthetic grafts. J Surg Res 123: 237–244.

57. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy Position statement. Cytotherapy 8: 315–317.

58. Dudek AZ, Neumelova I, Mayo K, Verfaille CM, Pitchford S, et al. (2003) Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood 101: 4687–4694.

59. Lord BI, Woolford LB, Wood LM, Czajkowski LG, McCourt M, et al. (1995) Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha. Blood 85: 3412–3415.

60. Pelas LM, Fukuda S (2006) Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp Hematol 34: 1010–1020.

61. Thevenot FT, Nair AM, Shen, J, Lecl F, Ko CY, et al. (2010) The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 31: 3997–4008.

62. Zhang F, Tsai S, Kato K, Yamanoouchi D, Wang C, et al. (2009) Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J Biol Chem 284: 17564–17574.

63. Zhang J, Lu SH, Liu YJ, Peng Y, Han ZC (2004) Platelet factor 4 enhances the adhesion of normal and leukemic hematopoietic stem/progenitor cells to endothelial cells. Leuk Res 28: 631–638.

64. Nair AM, Tsai YT, Shah KM, Shen J, Weng H, et al. (2013) The effect of erythropoietin on autologous stem cell-mediated bone regeneration. Biomaterials 34: 7364–7371.

65. Grunin E, Doll BA, Futrell FW, Schmait JP, Hollinger JO (2012) Demineralized bone matrix in bone repair: history and use. Adv Drug Deliv Rev 64: 1063–1077.

66. Tub SM, Singh AD (1976) The osteoinductive property of decalcified bone matrix. An experimental study. J Bone Joint Surg Br 60: 116–123.

67. Tuli SM, Singh AD (1976) The osteoinductive property of decalcified bone matrix. An experimental study. J Bone Joint Surg Br 60: 116–123.

68. Gandhi VC, Hughes HM, Ing TS, Daugirdas JT, Jablakow VR, et al. (1980) Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 140: 1201–1203.

69. Garosi G, Di Paolo N (2001) Inflammation and gross vascular alterations are characteristic histological features of sclerosing peritonitis. Kidney Int 61: 417–418.

70. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B (1996) Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 49: 506–511.

71. Fadare O, Bifulco C, Carter D, Parkash V (2002) Cartilaginous differentiation in peritoneal tissues: a report of two cases and a review of the literature. Mod Pathol 15: 770–778.

72. Woldanski KH (1994) Bone histogenesis mediated by nonosteogenic cells. Clin Orthop Relat Res 8: 15.